MDGL

As of 2026-10-26, MDGL scores 26out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. MDGL trades at $437.74, 47% above the band ceiling.

MDGL scores 26 out of 100 on QNTM's five-factor model — a low-conviction reading — at 26 the factor profile is among the weaker names in the universe. Its strongest factor is volume at 34 (soft), where trading volume confirms genuine accumulation, followed by quality at 32. The weakest is momentum at 16, where price trend is the soft spot. Among Healthcare stocks it sits in the lower 5% of Healthcare names by composite.

On valuation, MDGL is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 27. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on MDGL, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where MDGL sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for MDGL runs $197.43–$297.39. Current price $437.74 sits 47% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.